ARTICLE | Clinical News
AltheRx's solabegron meets overactive bladder endpoint
March 2, 2012 1:54 AM UTC
AltheRx Pharmaceuticals Inc. (Malvern, Pa.) said solabegron met the primary endpoint of reducing the mean number of incontinence episodes per 24 hours from baseline to week eight vs. placebo in a Phase II trial to treat overactive bladder. The double-blind, international trial enrolled 258 women with moderate to severe OAB symptoms. The product is an adrenergic receptor beta 3 (ADRB3) agonist. ...